Bristol-Myers announces efficacy data analysis from Phase 3 CheckMate -238 trial
Bristol-Myers Squibb announced results of a three-year analysis of efficacy data from the Phase 3 CheckMate -238 study evaluating adjuvant use of Opdivo 3 mg/kg versus Yervoy 10 mg/kg in patients with Stage III or Stage IV melanoma who were at high risk of recurrence following complete surgical resection. At three years of follow-up, Opdivo continues to demonstrate superior recurrence-free survival compared to Yervoy, the active control, with RFS rates of 58% and 45%, respectively. Distant-metastasis-free survival also continues to be significantly longer for Opdivo, with 36-month rates of 66% and 58%, respectively. Both RFS and DMFS benefit continue to be observed across key subgroups, including disease stages, BRAF mutation status and PD-L1 expression. No new safety data were generated as part of the 36-month analysis.